Physician profile
Stephanie Sanchez
NPI 1003130592
$2,657.06
in general payments reported to CMS, 2019-2025
26 companies · $450 in 2025
The $450 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $229 · 2022: $771 · 2023: $799 · 2024: $408 · 2025: $450.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,657.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,656.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $517.38 | 2021-2025 | |
| Novo Nordisk INC | $466.99 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $244.40 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $197.54 | 2021-2023 | Spravato |
| Renalytix Ai, INC. | $148.99 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Amgen INC. | $142.15 | 2021-2024 | Repatha, Otezla |
| Alnylam Pharmaceuticals INC. | $123.32 | 2023 | Amvuttra |
| Solta Medical, A Division of Bausch Health US, LLC | $114.47 | 2025 | Clear+Brilliant |
| Eisai INC. | $100.18 | 2024 | |
| Apellis Pharmaceuticals, INC. | $87.42 | 2022 | |
| Lilly USA, LLC | $68.03 | 2021-2023 | Trulicity, Mounjaro |
| Exact Sciences Corporation | $66.52 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astrazeneca Pharmaceuticals LP | $55.91 | 2022-2023 | Farxiga |
| Incyte Corporation | $39.58 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $35.70 | 2023 | Entyvio |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $28.69 | 2023 | Intellis Adaptivestim |
| Inspire Medical Systems, INC. | $28.42 | 2023 | Inspire |
| Teva Pharmaceuticals USA, INC. | $27.04 | 2022 | |
| Photonicare INC | $23.90 | 2023 | Otosight Middle Ear Scope |
| Otsuka America Pharmaceutical, INC. | $23.69 | 2024 | Rexulti |
| Convatec INC. | $22.37 | 2023 | |
| Siemens Medical Solutions USA, INC. | $21.79 | 2023 | Magnetom Altea |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.63 | 2024 | Jardiance |
| Abbott Laboratories | $18.70 | 2024 | Freestyle Libre 3 |
| Esperion Therapeutics, INC. | $18.38 | 2021 | |
| Idorsia Pharmaceuticals US INC | $14.87 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Sanchez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.